A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS)

Therapeutic Advances in Neurological Disorders

Volumn 3, Issue 1, 2010, Pages 3-13

  Remington, Gina M ^a   Treadaway, Katherine ^a   Frohman, Teresa ^a   Salter, Amber ^b   Stuve, Olaf ^c   Racke, Michael K ^d   Hawker, Kathleen ^d   Agosta, Federica ^e   Sormani, Maria Pia ^e   Filippi, Massimo ^e   Frohman, Elliot M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Veterans Administration Hospital   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

CellCept; immunosuppression; mycophenolate mofetil; relapsing remitting multiple sclerosis; treatment na ve

Indexed keywords

BETA1A INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; PLACEBO;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HAIR LOSS; HEADACHE; HUMAN; INSOMNIA; LABORATORY TEST; LIBIDO; MALE; MEMORY; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SIDE EFFECT; SINUSITIS; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION;

EID: 77953453035     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285609355851     Document Type: Article

References (49)

1. Aharoni, R., Kayhan, B., Eilam, R., Sela, M. and Arnon, R. ( 2003) Glatiramer acetate-specific T cells in the brain express T helper 2 / 3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA 100: 14157-14162.
2. Ameen, M., Smith, H.R. and Barker, J.N. ( 2001) Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis. Clin Exp Dermatol 26: 480-483.
3. Barten, M.J., van Gelder, T., Gummert, J.F., Boeke, K., Shorthouse, R., Billingham, M.E. et al. (2002 a) Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant 2: 719-732.
4. Barten, M.J., van Gelder, T., Gummert, J.F., Shorthouse, R., Morris, R.E. et al. (2002 b) Novel assays of multiple lymphocyte functions in whole blood measure: new mechanisms of action of mycophenolate mofetil in vivo. Transpl Immunol 10: 1-14.
5. Berger, J.R. and Houff, S. (2009) Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann Neurol 65: 367-377.
6. Boster, A., Edan, G., Frohman, E., Hauser, S., Javed, A., Stuve, O. et al. (2008) Intense immunosuppression in rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurology 7: 173-183.
7. Chaudhry, V., Cornblath, D.R., Griffin, J.W., O'Brien, R., Drachman, D.B. et al. (2001) Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 56: 94-96.
8. Ciafaloni, E., Massey, J.M., Tucker-Lipscomp, B. and Sanders, D.B. ( 2001) Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 56: 97-99.
9. Cohen, J.A., Imrey, P.B., Calabresi, P.A., Edwards, K.R., Eickenhorst, T., Felton WL 3rd. et al. (2009) Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 72: 535-541.
10. Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernandez, O. et al. (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357: 1576-1582.
11. Daina, E., Schieppati, A. and Remuzzi, G. ( 1999) Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med 130: 422-426.
12. Filippi, M., Bozzali, M., Rovaris, M., Gonen, O., Kesavadas, C., Ghezzi, A. et al. (2003) Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126: 433-437.
13. Frohman, E.M., Filippi, M., Stüve, O., Waxman, S.G., Corboy, J., Phillips, J.T. et al. (2005 a) Characterizing the mechanisms of progression in multiple sclerosis. Arch Neurol 62: 1345-1356.
14. Frohman, E.M., Stüve, O., Havrdova, E., Corboy, J., Achiron, A., Zivadinov, R. et al. (2005 b) Therapeutic considerations for disease progression in multiple sclerosis. Arch Neurol 62: 1519-1530.
15. Frohman, E.M., Brannon, K., Racke, M.K. and Hawker, K. ( 2004) Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 27: 80-83.
16. Frohman, E.M., Raine, C. and Racke, M.K. ( 2006) Multiple sclerosis: the plaque and its pathogenesis. New Engl J Med 354: 942-955.
17. Gelber, A.C., Nousari, H.C. and Wigley, F.M. ( 2000) Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 27: 1542-1545.
18. Goodin, D., Frohman, E.M., Garmany, G.P., Halper, J., Likosky, W.H., Lublin, F.D. et al. (2002) Disease modifying therapies in multiple sclerosis. Neurology 58: 169-178.
19. Gorson, K.C., Amato, A.A. and Ropper, A.H. ( 2004) Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 63: 715-717.
20. Hauser, R.A., Malek, A.R. and Rosen, R. ( 1998) Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 51: 912-913.
21. Hong, J., Li, N., Zhang, X., Zheng, B. and Zhang, J.Z. ( 2005) Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 102: 6449-6454.
22. Ishida, H., Tanabe, K., Furusawa, M., Ishizuka, T., Shimmura, H., Tokumoto, T. et al. (2002) Mycophenolate mofetil suppresses the production of anti-blood type antibodies after renal transplantation across the blood brain barrier: ELISA to detect humoral activity. Transplantation 74: 1187-1189.
23. Jacobs, L.D., Beck, R.W., Simon, J.H., Kinkel, R.P., Brownscheidle, C.M., Murray, T.J. et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343: 898-904.
24. Jonsson, C. and Carlsten, H. ( 2002) Mycophenolic acid inhibits inosine 5 (') monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages. Cell Immunol 216: 93-101.
25. Kappos, L., Polman, C.H., Freedman, M.S., Edan, G., Hartung, H.P., Miller, D.H. et al. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67: 1242-1249.
26. Karandikar, N.J., Crawford, M.P., Yan, X., Ratts, R.B., Brenchley, J.M., Ambrozak, D.R. et al. (2002) Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest 109: 641-649.
27. Karim, M.Y., Alba, P., Cuadrado, M.J., Abbs, I.C., D'Cruz, D.P., Khamashta, M.A. et al. (2002) Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology, Oxford 41: 876-882.
28. Kieseier, B., Wiendl, H., Hartung, H.P., Stuve, O. et al. (2009) The future of multiple sclerosis therapy. Pharmacological Research 60: 207-211.
29. Kinkel, R.P., Kollman, C., O'Connor, P., Murray, T.J., Simon, J., Arnold, D. et al. (2006) IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66: 678-684.
30. Lui, S.L., Tsang, R., Wong, D., Chan, K.W., Chan, T.M., Fung, P.C. et al. (2002) Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL / lpr mice. Lupus 11: 411-418.
31. Mowzoon, N., Sussman, A. and Bradley, W.G. ( 2001) Mycophenolate (Cellcept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 185: 119-122.
32. Noseworthy, J.H., Lucchinetti, C., Rodriguez, M. and Weinshenker, B.G. ( 2000) Medical progress: multiple sclerosis. N Engl J Med 343: 938-952.
33. O'Connor, P.W., Li, D., Freedman, M.S., Bar-Or, A., Rice, G.P., Confavreux, C. et al. (2006) A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66: 894-900.
34. Polman, C.H., O'Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
35. Polman, C.H., Reingold, S.C., Edan, G., Filippi, M., Hartung, H.P., Kappos, L. et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol 58: 840-846.
36. Quemeneur, L., Flacher, M., Gerland, L.M., Ffrench, M., Revillard, J.P., Bonnefoy-Berard, N. et al. (2002) Mycophenolic acid inhibits IL-2 dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis. J Immunol 169: 2747-2755.
37. Rudick, R.A., Stuart, W.H., Calabresi, P.A., Confavreux, C., Galetta, S.L., Radue, E.W. et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911-923.
38. Schanz, S., Ulmer, A., Rassner, G. and Fierlbeck, G. ( 2002) Successful treatment of subacute cutaneous lupus erythematosis with mycophenolate mofetil. Br J Dermatol 147: 174-178.
39. Schneider, C., Gold, R., Reiners, K. and Toyka, K.V. ( 2001) Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol 46: 79-82.
40. Schneider, C., Gold, R., Schafers, M. and Toyka, K.V. ( 2002) Mycophenolate mofetil in the therapy of poly-myositis associated with a polyautoimmune syndrome. Muscle Nerve 25: 286-288.
41. Schrader, P., Mooser, G., Peter, R.U. and Puhl, W. ( 2002) Preliminary results in the therapy of psoriatic arthritis with mycophenolate mofetil. Z Rheumatol 61: 545-550.
42. Smith, S.M., Zhang, Y., Jenkinson, M., Chen, J., Matthews, P.M., Federico, A. et al. (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage 17: 479-489.
43. Stuve, O., Dooley, N.P., Uhm, J.H., Antel, J.P., Francis, G.S., Williams, G. et al. (1996) Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 40: 853-863.
44. Tennakoon, D.K., Mehta, R.S., Ortega, S.B., Bhoj, V., Racke, M.K. and Karandikar, N.J. ( 2006) Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 176: 7119-7129.
45. Treadaway, K., Cutter, G., Salter, A., Lynch, S., Simsarian, J., Corboy, J. et al. (2009) Factors that influence adherence with disease-modifying therapy in MS. J Neurol 256: 568-576.
46. Waiser, J., Budde, K., Braasch, E. and Neumayer, H.H. ( 1999) Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil. Am J Kidney Dis 34: e9.
47. Weiner, H.L. ( 2008) A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol 255 (Suppl. 1): 3-11.
48. Weiner, H.L. ( 2009) The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 65: 239-248.
49. Zivadinov, R., Reder, A.T., Filippi, M., Minagar, A., Stuve, O., Lassman, H. et al. (2008) Mechanisms of action of disease modifying therapy in MS: the relationship of the dynamics of short and long term changes in brain volume. Neurology 71: 136-144.